 of the inﬂammatory reaction.
Evidence. A systematic review and meta-analysis of 13
studies with sulodexide19 included 1901 participants with
CVD at any stage of the disease, classiﬁed or nonclassiﬁed,
was considered. Sulodexide decreased the intensity of
pain, cramps, heaviness, edema, total symptom score and
reduced inﬂammatory mediators in patients with CVD